Sanofi SA (SASY.PA)
ZURICH Swiss biotech company Actelion , days before agreeing to a $30 billion bid by Johnson & Johnson , found a rival offer to be as attractive but went with J&J because its offer provided more certainty, a filing showed on Thursday.
* J&J's $280 per share tender offer to start March 3 (Recasts with rival offer, adds background throughout)
Feb 13 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:
* Ipsen to acquire a portfolio of select consumer healthcare products from Sanofi
PARIS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.
PARIS, Feb 13 Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits.
Feb 12 Drugmaker Sanofi is close to selling some over-the-counter products to Ipsen SA, in a deal that could be valued at nearly 100 million euros ($106.18 million), Bloomberg reported.
BRIEF-Sanofi nearing deal to sell some over-the-counter products to Ipsen for about 100 mln euros- Bloomberg, citing source
* Sanofi nearing agreement to sell some over-the-counter products to Ipsen; deal may be announced as soon as Monday- Bloomberg, citing source
Regeneron Pharmaceuticals Inc Chief Executive Leonard Schleifer signaled that the U.S. biotech was on track to reduce its reliance on its flagship drug Eylea, as the company awaits the approval of two potential blockbuster treatments.
* Shares rise as much as 4 pct (Adds conference call details; updates shares)